Evidence map›Paper›PMID 42503514›Full record

ArticleSignal transduction and targeted therapy2026

Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming.

Fanlian Zeng, Fulei Zhao, Pei Zhou, Ya Li, Xiaoyan Wang, Yawen Hu, Jiadong Yu, Guolin Li, Chengcheng Yue, Yuting Feng and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Fanlian Zeng *Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Fulei Zhao *Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.ORCID http://orcid.org/0000-0002-8866-4041
Pei Zhou *Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Ya LiDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xiaoyan WangDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yawen HuDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Jiadong YuDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Guolin LiDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Chengcheng YueDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yuting FengDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Nongyu HuangDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xiaochi SunDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Xinmeng WangDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Shishi HuangDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Mingxiang HeDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Wenling WuDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Kaijun CuiDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Jiong LiDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. lijionghh@scu.edu.cn.ORCID http://orcid.org/0000-0002-3742-630X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81472650National Natural Science Foundation of China (National Science Foundation of China) 81673061National Natural Science Foundation of China (National Science Foundation of China) 82503132
6 · The paper itself

Abstract

Conventional type 1 dendritic cells (cDC1s) play a pivotal role in initiating CD8

Indexed as

Chenodeoxycholic AcidCross-PrimingDendritic CellsNeoplasmsReceptors, G-Protein-CoupledAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansMiceChenodeoxycholic AcidGPBAR1 protein, humanGpbar1 protein, mouseReceptors, G-Protein-Coupled

Identifiers

PMID42503514
PMCPMC13402744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.